Name of Policy: **Definity (Perflutren Lipid Microsphere)**

Policy Number: 3364-106-E10

Department: Heart Station

Approving Officer: Chief Executive Officer - UTMC

Responsible Agent: Director Cardiovascular Services

Scope: University of Toledo Medical Center Heart Station

Effective Date: 10/2019

Initial Effective Date: 6/20/2002

---

(A) **Policy Statement**

The ECHO Technologist will provide safe and effective care when using Definity contrast on a patient in a manner to insure that quality care is given and quality results are achieved.

(B) **Purpose of Policy**

Activated Definity injectable suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial borders. Activated Definity can be used during Exercise Stress, Dobutamine Stress, Resting Echocardiograms and Transesophageal Echocardiograms.

(C) **Procedure**

**Criteria for Definity Usage**

Basic criteria may include, but not limited to, the following:

1. Stress Echocardiogram-Definity may be used if two or more of left ventricular wall segments are poorly visualized on the baseline views.

2. Transthoracic/Trans esophageal Echocardiograms-Definity may be used if two or more left ventricular wall segments are poorly visualized or if apical views are suspicious for a thrombus. Definity may also be used to enhance Doppler signals. Definity may also be used to assess for aortic dissection.

**Contraindications**

- Do not administer Definity to patients with known or suspected hypersensitivity to Perflutren.

**Warnings and Precautions**

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Always have resuscitation equipment and trained personnel readily available.

**Adverse Reactions**

The most common adverse reactions (>0.5%) are headache, back/renal pain, flushing, nausea, chest pain, injection site reactions, and dizziness.
## Protocol

If the criteria for Definity use are met as mentioned above, the following will be implemented:

1. The sonographer or physician will assess the need for Definity in compliance with the procedure.
2. The physician will oversee the order.
3. The RN or Nuclear Technologist should be contacted to start the IV if needed.
4. Use bolus of Definity.
5. The RN or physician will inject the activated Definity.
6. Remove IV and release patient if asymptomatic.

<table>
<thead>
<tr>
<th>Approved by:</th>
<th>Review/Revision Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>/s/ Todd Korzec</td>
<td>5/04</td>
</tr>
<tr>
<td>Director Cardiovascular Services</td>
<td>6/05</td>
</tr>
<tr>
<td>/s/ Samer J. Khouri, MD</td>
<td>7/07</td>
</tr>
<tr>
<td>Director, Non-invasive Cardiac Imaging</td>
<td>10/07</td>
</tr>
<tr>
<td>/s/ Dan Barbee, RN, BSN, MBA</td>
<td>1/09</td>
</tr>
<tr>
<td>Chief Executive Officer – UTMC</td>
<td>8/25/2010</td>
</tr>
<tr>
<td></td>
<td>6/2013</td>
</tr>
<tr>
<td></td>
<td>3/2016</td>
</tr>
<tr>
<td></td>
<td>10/2019</td>
</tr>
</tbody>
</table>

Next Review Date: 10/2022

Policies Superseded by This Policy: